Anika Therapeutics, INC

Anika Therapeutics reports record Q2 revenue, significant gross margin expansion, and raises full-year guidance, driven by strong commercial and OEM channel performance.

Anika Therapeutics, Inc. has entered into a Fifth Amendment to its Credit Agreement, increasing its senior revolving line of credit to $50 million with an option to extend by another $50 million.

Anika Therapeutics reported a 13% increase in first-quarter 2026 revenue to $29.6 million, driven by strong performance in both OEM and Commercial Channels, alongside a significant improvement in gross margin to 64.2%.

Anika Therapeutics reported Q4 and full-year 2025 financial results, meeting revenue and exceeding adjusted EBITDA targets, while announcing a key executive transition.

Anika Therapeutics announced a leadership transition with Steve Griffin appointed CEO, Cheryl Blanchard becoming Executive Chair, and reaffirmed its fiscal year 2025 financial guidance.

Anika Therapeutics reported a 6% revenue decrease in Q3 2025, driven by OEM channel declines, while its Commercial Channel grew 22% and the final Hyalofast PMA module was filed with the FDA.

Anika Therapeutics reports significant revenue growth and improved gross margins in Q2 2026, driven by strong performance in its OEM and Commercial Channels.

Anika Therapeutics reported a net loss of $2.3 million in Q3 2025, with revenue declining 6% year-over-year, primarily due to lower OEM channel pricing, despite growth in its Commercial Channel.

Anika Therapeutics reported a significant net loss and revenue decline in the second quarter of 2025, compounded by its Hyalofast cartilage repair therapy failing to meet co-primary endpoints in a pivotal U.S. Phase III trial.

Anika Therapeutics' Q1 2025 results reveal a revenue decrease of 10% due to lower OEM sales and discontinued operations, as the company focuses on OA Pain Management and Regenerative Solutions businesses.

Anika Therapeutics reported a net loss for Q3 2024 and announced the sale of its Arthrosurface business and plans to divest Parcus Medical to focus on core HA technology.

Anika Therapeutics experienced a slight revenue decrease in Q2 2024, alongside a reduction in net loss compared to the same period last year, as the company navigates strategic changes and market dynamics.

Anika Therapeutics shifts strategy to concentrate on osteoarthritis pain management and regenerative solutions, divesting Arthrosurface and Parcus Medical.

Anika Therapeutics has filed an amendment to its annual report on Form 10-K, primarily to include information required in Part III regarding directors, executive officers, and corporate governance.

Anika Therapeutics details executive retention agreements, director compensation policies, and subsidiary information in its latest 10-K filing with the SEC.

CEO Stephen D. Griffin acquired 12,840 shares of Anika Therapeutics common stock through the vesting of restricted stock units.

Anika Therapeutics Director John B. Henneman III has acquired 5,000 shares of common stock.

President and CEO Stephen D. Griffin purchased 12,200 shares of Anika Therapeutics common stock on April 30, 2026.

Anika Therapeutics, Inc. granted Restricted Stock Units and Premium Priced Stock Appreciation Rights to SVP, CAO & Treasurer Ian McLeod, aligning executive incentives with long-term shareholder value.

Anika Therapeutics' EVP, General Counsel, and Corporate Secretary, David Colleran, reported the vesting of restricted stock units and performance-based units, along with associated tax withholdings.

Anika Therapeutics CEO Stephen D. Griffin reported the vesting of restricted stock units and performance stock units, alongside shares withheld for tax obligations.

Anika Therapeutics, Inc. has issued its proxy statement for the upcoming Annual Meeting of Stockholders on June 18, 2026, detailing proposals including director elections, auditor ratification, executive compensation approval, and amendments to equity incentive and employee stock purchase plans.

Anika Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Anika Therapeutics is asking stockholders to approve an amendment to its 2017 Omnibus Incentive Plan to increase the number of authorized shares, aiming to attract and retain key talent for its growth strategy.

Anika Therapeutics issues a statement disagreeing with Glass Lewis's recommendation against the election of director Stephen O. Richard, asserting his independence and urging stockholders to vote in his favor.

Anika Therapeutics is focusing on profitable growth and expects over 75% adjusted EBITDA growth in 2024 through strategic spending cuts and product portfolio optimization.

Caligan Partners LP updated its Schedule 13D filing for Anika Therapeutics, Inc., detailing derivative agreements representing 4.3% economic exposure.

Caligan Partners LP and David Johnson updated their beneficial ownership in Anika Therapeutics, Inc., maintaining a 9.95% stake and disclosing cash-settled derivative agreements.

Vanguard Capital Management has reported a 4.95% ownership stake in Anika Therapeutics Inc. as of June 30, 2026.

BlackRock Portfolio Management LLC has disclosed a beneficial ownership of 544,710 shares, representing 4.1% of the outstanding common stock of Anika Therapeutics Inc.

Vanguard Capital Management has reported a beneficial ownership of 5.19% in Anika Therapeutics Inc., holding 695,697 shares as of March 31, 2026.

The Vanguard Group has reported 0% beneficial ownership of Anika Therapeutics Inc. common stock following an internal realignment.

Trigran Investments and its principals have filed an amended Schedule 13G, reporting a 1.2% beneficial ownership stake in Anika Therapeutics, Inc. as of December 31, 2025.

Trigran Investments and its principals have disclosed an 11.2% beneficial ownership stake in Anika Therapeutics, Inc., reserving the right for director nominations.